Bromfenac
Bromfenac is a pharmaceutical drug with 15 clinical trials. Historical success rate of 93.3%.
Success Metrics
Based on 14 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
0
Mid Stage
13
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
93.3%
14 of 15 finished
6.7%
1 ended early
0
trials recruiting
15
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery
Effectiveness of Periocular Drug Injection in CATaract Surgery
Control of Pain in Intravitreal Injections Using Topical NSAIDs
Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%
Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.
Clinical Trials (15)
Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery
Effectiveness of Periocular Drug Injection in CATaract Surgery
Control of Pain in Intravitreal Injections Using Topical NSAIDs
Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%
Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.
Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial
PRevention of Macular EDema After Cataract Surgery
Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy
Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery
Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis
Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery
A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification
Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%
Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase
All 15 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 15